ReviewFrontiers in pharmacology2025

Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment.

Xinyue Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.